BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...
BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...
Brixadi (buprenorphine) is a brand-name injection that’s prescribed for opioid use disorder. As with other drugs, Brixadi can cause side effects, such as injection site reactions and respiratory ...
Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...
PLYMOUTH MEETING, Pa., June 25, 2024 /PRNewswire/ -- Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open. The analysis ...
Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...
As the United States' opioid epidemic rages on, health officials are busy looking for ways to help with the response. Now, right on the heels of the FDA's approval for a new overdose rescue medication ...
SILVER SPRING, Md., May 23, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results